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Abstract
Background: Publication bias is generally ascribed to authors and sponsors failing to submit studies with negative results,
but may also occur after submission. We evaluated whether submitted manuscripts on randomized controlled trials (RCTs)
with drugs are more likely to be accepted if they report positive results.
Methods: Manuscripts submitted from January 2010 through April 2012 to one general medical journal (BMJ) and seven
specialty journals (Annals of the Rheumatic Diseases, British Journal of Ophthalmology, Gut, Heart, Thorax, Diabetologia, and
Journal of Hepatology) were included, if at least one study arm assessed the efficacy or safety of a drug and a statistical test
was used to evaluate treatment effects. Publication status was retrospectively retrieved from submission systems or
provided by journals. Sponsorship and trial results were extracted from manuscripts and classified according to predefined
criteria. Main outcome measure was acceptance for publication.
Results: Of 15,972 manuscripts submitted, 472 (3.0%) were drug RCTs, of which 98 (20.8%) were published. Among
submitted drug RCTs, 287 (60.8%) had positive and 185 (39.2%) negative results. Of these, 60 (20.9%) and 38 (20.5%),
respectively, were published. Manuscripts on non-industry trials (n = 213) reported positive results in 138 (64.8%)
manuscripts, compared to 71 (47.7%) on industry-supported trials (n = 149), and 78 (70.9%) on industry-sponsored trials
(n = 110). Twenty-seven (12.7%) non-industry trials were published, compared to 27 (18.1%) industry-supported and 44
(40.0%) industry-sponsored trials. After adjustment for other trial characteristics, manuscripts reporting positive results were
not more likely to be published (OR, 1.00; 95% CI, 0.61 to 1.66). Submission to specialty journals, sample size, multicentre
status, journal impact factor, and corresponding authors from Europe or US were significantly associated with publication.
Conclusions: For the selected journals, there was no tendency to preferably publish manuscripts on drug RCTs that
reported positive results, suggesting that publication bias may occur mainly prior to submission.
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Introduction
Publication bias refers to the selective publication of research
findings depending on the nature and direction of results [1] and
has been widely studied. Studies reporting positive results are more
likely to be published [2–4], which may cause meta-analyses based
on published reports to overestimate the size of apparent
treatment effects. Pharmaceutical industry sponsorship has par-
ticularly been associated with publication of favourable out-
comes.[5–8] Publication bias is generally ascribed to authors and
sponsors failing to submit studies with negative results, but may
also occur once manuscripts have been submitted to jour-
nals.[9,10]
A limited number of studies have systematically evaluated
publication bias in editorial decision making. Olson et al. assessed
manuscripts submitted to JAMA, and found no difference in
publication rates between manuscripts with positive versus
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negative results.[11] Lee et al. found similar results for manuscripts
submitted to BMJ, the Lancet and Annals of Internal Medi-
cine.[12] Lynch et al. and Okike et al. assessed submissions to The
Journal of Bone and Joint Surgery, and found no evidence for
publication bias by editors.[13,14] Overall, these studies suggest
that submitted manuscripts with positive results are not more likely
to be published, which was confirmed by a recent meta-
analysis.[15]
However, these studies had certain limitations. Most were
prospective studies, so editors and reviewers may have been aware
that some investigation was in progress.[11–13] This possibly
influenced their decision making, even if they were not informed
about the study hypothesis. Olson et al. and Lee et al. included
large general medical journals with high impact factors, and their
results may not be generalizable to specialty journals or journals
with fewer submissions, fewer editors or lower circulation.[11]
Two studies were limited to orthopaedic journals, and resulting
findings may not apply to other specialties.[13,14] Moreover,
publication bias may affect studies with various designs and
interventions differently. Olson et al. included manuscripts on
controlled trials, while others enrolled manuscripts reporting
original research, regardless of study design.[12–14] None of the
studies that followed manuscripts submitted to journals included
papers based on the intervention tested, while publication bias has
predominantly been researched and described for drug tri-
als.[4,6,7,16,17]
Acceptance rates may also depend on sponsorship, next to study
results. Publication of industry-sponsored trials has been associated
with an increase in journal impact factors [18], as impact factors
depend on citation rates and industry-sponsored trials are more
frequently cited than non-profit trials.[19,20] Moreover, journals
create revenue through reprint sales, and industry funding of trials
has been associated with high numbers of reprint orders.[21,22]
Lynch et al. found that commercially funded research was more
likely to be published, while Olson et al. reported no difference
according to funding source.[11,13] However, neither of these
studies focused on drug research, in which industry funding
appears to be most abundant.
In this study, we retrospectively assessed manuscripts on
randomized controlled trials (RCTs) with drugs submitted to one
general medical journal and seven specialty journals, and
evaluated acceptance rates of manuscripts reporting positive
versus negative results. We hypothesized that negative trials were
less likely to be published. Submission rates of positive versus
negative studies were compared by sponsor type and the influence
of sponsorship on acceptance rates was determined.
Methods
Selection of journals
Editors of six major general medical journals were asked for
their cooperation to provide access to submitted manuscripts, peer
review comments, and final decisions on publication. BMJ agreed
to participate and the BMJ Group also provided access to data of
BMJ specialty journals. In addition, other European specialty
journals were asked to participate. All journals were selected based
on 1. impact factor (journals indexed with the highest impact
factors within subject categories, according to the Institute for
Scientific Information Journal Citation Report 2011); and 2. the
number of drug RCTs published in 2010–2011, determined on
the basis of a PubMed search. As a result, publication outcomes
were studied for one general medical journal and seven specialty
journals: BMJ, Annals of the Rheumatic Diseases, British Journal
of Ophthalmology, Gut, Heart, Thorax (all from the BMJ Group),
Diabetologia, and Journal of Hepatology.
Selection of submitted manuscripts
Original research manuscripts submitted between January 1,
2010 and April 30, 2012 were screened for eligibility by one
author. The study time frame per journal was based on the
retrospective period for which all required data, regardless of the
publication status of manuscripts, was completely available in
manuscript submission systems at the time of data extraction.
Manuscripts reporting results of RCTs were selected, if at least one
study arm assessed the efficacy or safety of a drug intervention
(including vaccines, biologics, dietary supplements, and herbal
medicinal products) and a statistical test was used to evaluate
treatment effects. Post-hoc and subgroup analyses and follow-up
studies of drug RCTs were included.
Data extraction
Data were extracted retrospectively by one author using a
standardized data extraction form. Primary outcome was accep-
tance for publication. Publication status and peer review details
were retrieved from submission systems or provided by journals.
Manuscripts were assessed as outright rejected, rejected after
external peer review, or accepted for publication. Information on
trial results and sponsorship was extracted from manuscripts. Data
on study characteristics previously examined for association with
publication (sample size, number of centres, corresponding
author’s country of residence [11–13]) were also retrieved.
Manuscripts were searched for registration numbers to determine
whether studies were registered in a trial registry that complies
with requirements of the International Committee of Medical
Journal Editors (ICMJE).[23] All included journals required trial
registration in their instructions to authors.
Classification of results and sponsorship
Trial results and sponsorship were classified based on consensus
between two authors according to predefined criteria.[24] Briefly,
outcomes were scored as positive if results reported for the primary
endpoint were statistically significant (p,0.05 or 95% confidence
interval [CI] for difference excluding 0 or 95% CI for ratio
excluding 1) and supported the efficacy of the test drug, and
negative if they did not. For equivalence and non-inferiority trials,
results were classified as positive if treatments were equivalent. If
the primary endpoint was a safety parameter, trials were classified
as positive if the test drug was as safe as or safer than control.
When explicitly hypothesized that the test drug was expected to be
safer than control, results were categorized as negative if
treatments were equally harmful. If no primary outcome was
stated for a trial or multiple primary endpoints were selected,
results were classified based on the statistical significance and
direction of most (primary) outcomes (.50%). Studies were
classified as non-industry, industry-supported or industry-spon-
sored trials. For non-industry trials, no associations with pharma-
ceutical companies were reported in the manuscript. Studies
reporting donation of study medication or placebos by a
manufacturer, studies stating receipt of financial support from a
pharmaceutical company and studies with authors affiliated to
industry were classified as industry-supported trials. For industry-
sponsored trials, a pharmaceutical company was explicitly
described as the study sponsor, or the company funding the trial
was reported to have participated in the study design, data
collection, analysis, preparation of the manuscript, and/or the
decision to publish. When doubt remained over sponsorship,
Publication Bias in Editorial Decision Making
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information in the trial registry took precedence over other
information (if registered).
Statistical analysis
The association between publication and trial results and other
characteristics was first analyzed using univariate logistic regres-
sion. Associations between acceptance (versus rejection) and trial
characteristics were estimated with odds ratios (ORs) and 95%
CIs. P-values were not adjusted for multiple comparisons and P,
.05 was considered statistically significant. To control for several
characteristics simultaneously, multiple logistic regression was used
and ORs were calculated. As 98 submitted manuscripts were
accepted in this study, nine predictors could be entered in the
model simultaneously, with ten acceptances per predictor. Besides
the primary analysis (accepted vs all rejected manuscripts), two
additional multivariable analyses were performed to compare
accepted manuscripts with those outright rejected or rejected after
peer review. These sensitivity analyses were conducted to assess
whether the effects of the covariates were dependent on the type of
rejection, i.e. whether the decision to reject manuscripts after
initial editorial screening versus after peer review was of influence
on the association between positive results and acceptance.
Statistical analyses were performed using SPSS software (version
20; Chicago, Illinois).
Ethics
To assure confidentiality of information in manuscripts and
submission systems, the authors signed confidentiality agreements
before gaining access to the data. As standard editorial processes
were unchanged, authors and peer reviewers were not informed
about this study. Approval from a research ethics committee was
not required, as this study involved no human participants.
Results
From January 2010 through April 2012, 15,972 manuscripts
reporting original research were submitted to eight journals, of
which 472 (3.0%) met all inclusion criteria. Ninety-eight manu-
scripts (20.8%) were published, 221 (46.8%) were outright rejected
and 152 (32.2%) were rejected after peer review. One manuscript
(0.2%) was withdrawn by authors before editorial decisions were
made (Figure 1).
Among 472 drug RCTs, 287 (60.8%) had positive results and
185 (39.2%) had negative results (Table 1). Of these, 135 (47.0%)
and 86 (46.5%), respectively, were rejected immediately, and 91
(31.7%) and 61 (33.0%) after peer review. In total, compared to
the number of submitted manuscripts, 60 (20.9%) positive studies
were published compared to 38 (20.5%) negative studies.
Publication outcomes of manuscripts submitted to each individual
journal are shown in Table 1. For all journals except Thorax, the
proportion of submitted manuscripts with positive results outnum-
bered those with negative results. In the BMJ, British Journal of
Ophthalmology, Diabetologia, Gut, Heart, and Journal of
Hepatology, a higher proportion of submitted manuscripts with
negative results were published, while in Annals of the Rheumatic
Diseases and Thorax a higher proportion of positive studies were
published.
Submitted manuscripts reporting non-industry trials (n = 213)
had positive results in 138 manuscripts (64.8%), compared to 71
manuscripts (47.7%) on industry-supported trials (n = 149), and 78
manuscripts (70.9%) on industry-sponsored trials (n = 110) (Ta-
ble 2). When all trials with industry involvement (n = 259) were
taken together, 149 submitted manuscripts (57.5%) reported
positive results. Twenty-seven (12.7%) non-industry trials were
published, compared to 27 (18.1%) industry-supported trials, and
44 (40.0%) industry-sponsored trials.
In the univariate analysis, manuscripts reporting positive results
were not more likely to be published compared to those with
negative results (OR, 1.03; 95% CI, 0.65–1.62) (Table 3).
Sponsorship was significantly associated with publication; indus-
try-sponsored trials were more likely to be published than non-
industry trials (OR, 4.59; 95% CI 2.64–8.00). Trial registration,
sample size, being a multicentre trial or follow-up study of an
RCT, a corresponding author from Europe or the US, and the
journal to which manuscripts are submitted were associated with
the chance of publication (Table 3).
In the multivariable analysis, accepted versus rejected manu-
scripts were compared after controlling for characteristics that
were significantly associated with publication in the univariate
analysis, or otherwise deemed important in relation to publication
(Table 4). After adjustment for these variables, acceptance rates
were not higher for trials with positive results than for trials with
negative results (OR, 1.00; 95% CI, 0.61–1.66). The association of
other factors with publication is shown in Table 4. In the
multivariable analysis, industry-sponsorship and trial registration
were no longer significantly associated with publication, while
journal impact factor and submission to specialty journals were
associated with an increased chance of acceptance. In the
multivariable analyses comparing accepted manuscripts with those
outright rejected or rejected after peer review, positive studies were
not more likely to be published (Table 4). Findings of these
analyses confirmed the primary analysis, as the direction of effects
found was equal in all analyses. However, most associations were
not statistically significant when comparing accepted manuscripts
with those rejected after peer review.
Discussion
This is the first study that evaluated publication bias of
manuscripts submitted to both a general medical journal and
multiple specialty journals. Submitted manuscripts on drug RCTs
were not more likely to be published if they reported positive
results, regardless of whether rejected manuscripts were peer
reviewed or not. This confirms findings of previous studies that
followed manuscripts submitted to journals.[11–14] The propor-
tion of submitted manuscripts with positive results outnumbered
those with negative results, suggesting that publication bias mainly
occurs prior to submission. This corresponds to findings of surveys
among investigators on reasons for non-publication of results
showing that studies primarily remained unpublished due to
investigator-related factors.[25,26]
Both submitted non-industry and industry-sponsored trials were
more likely to report positive results, in contrast to study findings
indicating that particularly industry sponsorship is associated with
favourable outcomes.[5,6] Interestingly, industry-sponsorship was
associated with publication in the univariate analysis, as was
previously found by Lynch et al.[13] This could be related to
editorial decisions, as incentives such as citation rates [19,20] and
reprint revenue [21,22] could favour the acceptance of these
studies. Trial registration resulted in an increased unadjusted OR
for publication, which may reflect that included journals adhere to
ICMJE policy requiring registration as a condition of consider-
ation for publication. Multicentre trials and studies enrolling more
than 100 participants were more likely to be published, which was
in agreement with findings of previous studies.[11,12]
Previous studies found that manuscripts whose corresponding
author was from the same country as the publishing journal were
more likely to be accepted.[12,13,27] We included European
Publication Bias in Editorial Decision Making
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journals only and found that having a corresponding author from
either Europe or the US increased the chance of publication. This
may result from a ‘familiarity effect’, leading reviewers and editors
to be more accepting of trials with familiar interventions, clinical
relevance, and language use.[13,28]
After adjustment for other trial characteristics, submission to
specialty journals was associated with publication. This seems
plausible, as acceptance rates of general medical journals are
known to be lower than those of specialty journals. A higher
journal impact factor increased the chance of publication, though
high impact journals generally have low acceptance rates. The
direction of this association may be explained by relatively high
acceptance rates found for two journals (Annals of the Rheumatic
Diseases, Journal of Hepatology). Studies with negative results
submitted to Annals of the Rheumatic Diseases and Thorax
seemed less likely to be published. In view of the fact that BMJ was
the only general medical journal that was included in this study
and the number of accepted manuscripts per journal was relatively
low, these data need to be interpreted with caution.
The retrospective design of this study overcomes limitations that
prospective studies on publication bias in editorial decision making
have. To study publication bias after manuscript submission,
collaboration from editors is essential. In prospective studies, the
decision-making behaviour of editors may be influenced by
awareness of an ongoing investigation [11], introducing bias into
the selection of manuscripts that are published. However, due to
this retrospective design, our study time frame was limited by the
retrospective availability of data in manuscripts submission
systems.
We included a general medical journal and specialty journals
across different medical specialties, which increases the general-
izability of our results compared to studies that only included large
general medical journals or an orthopaedic journal.[11–14]
However, we acknowledge that the journals included in our study
are merely a sample of all peer reviewed medical journals. It might
be that those journals that agreed to participate, did so based on
existing editorial policy to publish papers of scientific worth
regardless of the direction of results. As both BMJ and 5 of the 7
included specialty journals are published by the BMJ Group, the
results of this study may have been affected by clustering effects
based on publisher policy. Furthermore, investigators may prefer
to submit large, multi-centre, well-conducted studies to high
impact journals like those included in our study. If publication bias
is more likely to affect smaller studies, the inclusion of lower
impact journals that more commonly receive smaller, single-center
or negative studies might have influenced our results. However, no
study has found evidence for publication bias in editorial decision
making, irrespective of its design or included journals.
Other strengths include the objective selection criteria for
journals and manuscripts, analysis of confounding characteristics,
and classification of results and sponsorship based on predefined
criteria.[24] Assessment of results and establishing the role of the
funding source may appear to be straightforward, but in most
studies on publication bias, methods for classification of results and
Figure 1. Publication status of manuscripts submitted to eight medical journals during the study time frame.
doi:10.1371/journal.pone.0104846.g001
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sponsorship are only reported to a limited extent and definitions
used are inconsistent across studies.[24]
This study has certain limitations. During the assessment of
results and other characteristics, there was no blinding for
publication status. In a retrospective study, blinding for publica-
tion status would require editors to redact information made
available to investigators, which could introduce substantial bias.
Furthermore, the screening and selection of manuscripts and the
extraction of manuscript characteristics were performed by one
author, while this would ideally have been done by two
independent assessors. We have focused on drug RCTs, and our
results may not be generalizable to studies with different designs or
Table 3. Characteristics of submitted manuscripts and their association with publication: univariate analysis (accepted vs all
rejected).
Total number (%*) Published number (%1) Odds ratio (95% CI) P-value
Total manuscripts 472 (100) 98 (20.8)
Results .909
Positive results 287 (60.8) 60 (20.9) 1.03 (0.65–1.62)
Negative results 185 (39.2) 38 (20.5) 1.00
Journal (IF) .000
BMJ (14.093) 94 (19.9) 14 (14.9) 1.00
Ann Rheum Dis (8.727) 56 (11.9) 33 (58.9) 8.10 (3.72–17.64)
Brit J Ophthalmol (2.902) 22 (4.7) 4 (18.2) 1.25 (0.37–4.26)
Diabetologia (6.814) 135 (28.6) 16 (11.9) 0.76 (0.35–1.64)
Gut (10.111) 61 (12.9) 11 (18.0) 1.24 (0.52–2.95)
Heart (4.223) 24 (5.1) 3 (12.5) 0.81 (0.21–3.07)
J Hepatol (9.264) 44 (9.3) 13 (29.5) 2.37 (1.00–5.60)
Thorax (6.840) 36 (7.6) 4 (11.1) 0.71 (0.22–2.31)
Journal type .130
General medical journal 94 (19.9) 14 (14.9) 0.62 (0.33–1.15)
Specialty journal 378 (80.1) 84 (22.2) 1.00
Sponsorship .000
Industry-sponsored 110 (23.3) 44 (40.0) 4.59 (2.64–8.00)
Industry-supported 149 (31.6) 27 (18.1) 1.54 (0.86–2.75)
Non-industry 213 (45.1) 27 (12.7) 1.00
Industry involvement .000
Industry-supported or sponsored 259 (54.9) 71 (27.4) 2.62 (1.61–4.26)
Non-industry 213 (45.1) 27 (12.7) 1.00
Trial registration .010
Yes 374 (79.2) 87 (23.3) 2.41 (1.23–4.71)
No 98 (20.8) 11 (11.2) 1.00
Sample size .000
.100 participants 211 (44.7) 60 (28.4) 2.35 (1.49–3.70)
#100 participants 261 (55.3) 38 (14.6) 1.00
Number of centres .000
Multicentre 224 (47.5) 70 (31.2) 3.60 (2.22–5.84)
Single centre 248 (52.5) 28 (11.3) 1.00
Study type .022
Posthoc/subgroup analysis RCT 72 (15.3) 15 (20.8) 1.11 (0.60–2.07)
Follow-up study of RCT 19 (4.0) 9 (47.4) 3.73 (1.47–9.52)
RCT 381 (80.7) 74 (19.4) 1.00
Authors’ country of residence .003
Europe 224 (47.5) 57 (25.4) 2.42 (1.41–4.15)
US 71 (15.0) 19 (26.8) 2.57 (1.29–5.13)
Rest of the world 177 (37.5) 22 (12.4) 1.00
Journal impact factor 1.02 (0.95–1.09) .637
*Percentage of grand total of submitted manuscripts. 1 Percentage of row category that were accepted for publication. IF = journal impact factor, 2011.
doi:10.1371/journal.pone.0104846.t003
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interventions. The number of submitted drug RCTs varied
between journals. This could be related to medical specialty and
journal impact factor, but may also vary due to differences in
retrospective availability of data in submission systems of journals.
However, the proportion of drug RCTs among submitted
manuscripts was comparable for all journals. We included
European journals only, and editorial processes might slightly
differ compared to US journals. Our study included a represen-
tative sample of drug RCTs though, as more than half of all
submitted trials were from outside Europe.
In this study, we evaluated the overall editorial process after
manuscript submission and have not specifically examined the role
of peer reviewers in publication bias. Abbot and Ernst tested
whether publication bias was present during peer review, and
found that reviewers were no more likely to recommend
publication of a fictitious manuscript with positive results.[29]
However, Emerson et al. showed that a fabricated manuscript
reporting positive results was more often recommended for
publication than an otherwise identical manuscript reporting no
effect.[10] It is difficult to assess the extent to which editors’
decisions were reliant on reviewers’ comments in this study.
Kravitz et al. found that editors tend to place considerable weight
on reviewers’ recommendations.[30]
Finally, we have not determined quality scores for included
trials. Lee et al. found an increased chance of acceptance for
manuscripts with high quality scores.[12] The fact that multicentre
and large (.100 participants) trials were more likely to be
published can be seen as a proxy for quality. However, Lynch et
al. found no relation between quality scores and publication.[13]
Though observed acceptance rates did not favour manuscripts
with positive results in our study, negative studies may have been
of higher quality than positive studies, as was found by Lynch et
al.[13] This could result from authors believing that negative
papers are less likely to be accepted, therefore only submitting
those of high quality. As a consequence, submitted negative
manuscripts may be of higher quality than positive manuscripts.
Editorial bias occurs if submitted negative studies, although
superior in quality, are not more likely to be published.[31]
However, we found no differences between positive and negative
manuscripts regarding sample size and multicentre status.
To reduce potential publication bias after submission, editors
and peer reviewers could be blinded to results and discussion
sections of manuscripts.[9,32,33] Preliminary decisions would be
based on review of introduction and methods sections, and if
manuscripts pass this initial stage, the full article could be provided
to make a final evaluation. An RCT in which submitted
manuscripts are randomized to either traditional review or review
with initial blinding to results could confirm whether editors are
not more likely to accept positive studies. However, no journals
have implemented this two-stage review so far.
In conclusion, we found that for the sample of selected journals,
there was no tendency to preferably publish submitted manu-
scripts on drug RCTs that reported positive results. The
proportion of submitted manuscripts with positive results outnum-
bered those with negative results irrespective of sponsor type,
suggesting that publication bias may occur mainly before
manuscripts are submitted to journals.
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